Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Consumer Services
/
Allurion Technologies
ALUR
Allurion Technologies
Distributor Disruptions And FDA Delays Will Permit Modest Rebound
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
20 Aug 25
Updated
20 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$2.50
10.4% undervalued
intrinsic discount
20 Aug
US$2.24
Loading
1Y
-86.9%
7D
-6.7%
Author's Valuation
US$2.5
10.4% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$2.5
10.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-76m
64m
2021
2022
2023
2024
2025
2026
2027
2028
Revenue US$41.3m
Earnings US$4.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
15.30%
Consumer Services revenue growth rate
0.40%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.32%
Calculation
US$4.83m
Earnings '28
x
12.52x
PE Ratio '28
=
US$60.42m
Market Cap '28
US$60.42m
Market Cap '28
/
17.05m
No. shares '28
=
US$3.54
Share Price '28
US$3.54
Share Price '28
Discounted to 2025 @ 12.32% p.a.
=
US$2.50
Fair Value '25
